The Manila Times3d
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing ...
Nasdaq3d
ARS Pharmaceuticals Reports $7.3 Million in U.S. Net Revenue from neffy® and Highlights FDA Approval for Pediatric Use
ARS Pharmaceuticals, Inc. reported total U.S. net product revenue of $7.3 million for its neffy® (epinephrine nasal spray) in 2024, following its launch in late September. The company received ...
FierceBiotech4d
Fierce Biotech Fundraising Tracker '25: Ampersand raises $65M; Arbor adds $74M
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...
Healio2d
Headline News
Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...